Skip to content

Observation on the Clinical Efficacy and Mechanism Research of Yi Jin Jing in the Treatment of Axial Spondyloarthritis/Ankylosing Spondylitis

Observation on the Clinical Efficacy and Mechanism Research of Yi Jin Jing in the Treatment of Axial Spondyloarthritis/Ankylosing Spondylitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001619
Enrollment
Unknown
Registered
2025-08-28
Start date
2025-06-30
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

axSpA/AS

Interventions

Experimental group :Yijin Jing training
control group:Daily physical activity

Sponsors

Beijing University of Chinese Medicine Dongzhimen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The subjects included in this study must meet all of the following inclusion criteria: 1) Age >18 years old; 2) Gender is not limited; 3) It conforms to the classification criteria of axial spondyloarthritis (SpA) recommended by the International Ankylosing Spondylitis Assessment Working Group (ASAS) in 2009. 4) ASDAS-CRP: 1.3 - 3.5; 5) Those who have not used non-steroidal anti-inflammatory drugs within 2 weeks before enrollment; if non-steroidal anti-inflammatory drugs are being used, they need to be stably used within one month before enrollment. 6) For those who have not used biological agents within the 3 months prior to enrollment, if they have used biological agents, they need to use them stably for 1 month before they can be included. Those who have not participated in any non-pharmaceutical trials of traditional Chinese medicine within the four weeks prior to selection. 8) Voluntarily participate in the research and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Subjects with any of the following conditions will not be allowed to enter this trial: 1) Pregnant women women preparing for pregnancy or those who are breastfeeding; 2) Those who have had or are currently suffering from malignant tumors; 3) Those suffering from acute and/or chronic infectious diseases; 4) Those who have been diagnosed with other rheumatic and immune diseases; 5) Patients with other known diseases that require special attention in sports rehabilitation programs such as those with cardiovascular diseases or those whose cardiovascular risk assessment is at high risk; Patients who already have cervical vertebra bone Bridges; Patients who have undergone surgical treatment within the past 6 months; 6) Patients who have exercised regularly (such as yoga Tai Chi Baduanjin etc. at least 3 times a week 20 minutes each time) in the past 3 months; Patients who have previously used self-chronic disease management applications or received corresponding treatments; 7) Those whom the researchers consider not to meet the requirements for joining this clinical trial.

Design outcomes

Primary

MeasureTime frame
ASDASCRP;

Secondary

MeasureTime frame
ASDASCRP;ASAS20;BASDAI; BASFI ;BASMI;SF-36;rate of ASDASCRP<0.3;ASDASCRP ID;Rate of ASDAS LDA;Complete blood count;erythrocyte sedimentation Rate;C-reactive protein;

Countries

China

Contacts

Public ContactWanghailong

Beijing University of Chinese Medicine Dongzhimen Hospital

wanghailong@bucm.edu.cn13021044721

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026